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objective: Intensity-modulated radiotherapy (IMRT) has 
better normal-tissue sparing compared with 3-dimen-
sional conformal radiation (3DCRT). We sought to assess 
the impact of radiation technique on pathological and 
clinical outcomes in locally advanced non-small cell lung 
cancer (LANSCLC) treated with a trimodality strategy.
Methods: Retrospective review of LANSCLC patients 
treated from August 2012 to August 2018 at Sheba 
Medical Center, Israel. The trimodality strategy consisted 
of concomitant chemoradiation to 60 Gray (Gy) followed 
by completion surgery. The planning target volume (PTV) 
was defined by co-registered PET/CT. Here we compare 
the pathological regression, surgical margin status, local 
control rates (LC), disease free (DFS) and overall survival 
(OS) between 3DCRT and IMRT.
results: Our cohort consisted of 74 patients with mean 
age 62.9 years, male in 51/74 (69%), adenocarcinoma in 
46/74 (62.1%), stage 3 in 59/74 (79.7%) and chemotherapy 
in 72/74 (97.3%). Radiation mean dose: 59.2 Gy (SD ± 3.8). 
Radiation technique : 3DCRT in 51/74 (68.9%), IMRT in 
23/74 (31%). Other variables were similar between groups. 
Major pathological response (including pathological 
complete response or less than 10% residual tumor cells) 
was similar: 32/51 (62.7%) in 3DCRT and 15/23 (65.2%) 
in IMRT, p=0.83. Pathological complete response (pCR) 
rates were similar: 17/51 (33.3%) in 3DCRT and 8/23 
(34.8%) in IMRT, p=0.9. Surgical margins were negative in 
46/51 (90.1%) in 3DCRT vs. 17/19 (89.4%) in IMRT (p=1.0). 
The 2-year LC rates were 81.6% (95% CI 69-89.4%); DFS 58.3% 
(95% CI 45.5-69%) and 3-year OS 70% (95% CI57-80%). 
Comparing radiation techniques, there were no significant 
differences in LC (p=0.94), DFS (p=0.33) and OS (p=0.72). 
Conclusion: When used to treat LANSCLC in the neoadju-
vant setting, both IMRT and 3DCRT produce comparable 
pathological and clinical outcomes.
advances in knowledge: This study validates the real-
world effectiveness of IMRT compared to 3DCRT.
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introDuCtion
Radiation therapy is frequently used in the treatment of stage 
III non-small cell lung cancer (NSCLC), using a range of radi-
ation techniques. In three-dimensional conformal radiotherapy 
(3DCRT) several un-modulated fields (typically 3–4) are designed 
to deliver dose directed to the targets. With intensity-modulated 
radiotherapy (IMRT), optimized modulated radiation fields 
(typically 6–12) are designed to deliver the dose to the target. The 
shapes and intensities of each radiation field in IMRT are opti-
mized by means of computer algorithms to conform the dose to 
the target and to spare the nearby critical structures. Volumetric 
modulated arc therapy (VMAT) delivers radiation by rotating 
the gantry while the radiation beam remains on, simultaneously 
changing rotation speed, shape of the radiation field, and rate 
of delivered dose. Both IMRT and VMAT planning techniques 
improve target coverage and reduce radiation exposure to adja-
cent critical organs compared to 3DCRT.1,2
Yet, with these advanced technologies, a great deal of concern 
has been expressed regarding the potential for interplay-effect 
between target motion and collimator motion that may lead to 
insufficient tumor irradiation during IMRT and VMAT delivery. 
Tumor movement due to respiration introduces another level of 
complexity to IMRT treatment planning and delivery, as each 
radiation field segment may only cover a portion of the target 
volume at any particular time.3 Court et. al found that for most 
treatment techniques, these dose deviations averaged out after 
several fractions.4 However, prospective, randomized trial results 
directly comparing the efficacy and toxicity of 3DCRT vs IMRT 
for lung cancer have not yet been published.5
We therefore performed a retrospective study, comparing 
3DCRT vs IMRT. Primary endpoints included pathological 
response after chemoradiation and the margins of the resected 
surgical specimens; secondary endpoints were clinical outcomes 
including local control (LC) disease free survival (DFS) and 
overall survival (OS). We hypothesized that the two technolo-
gies produce the same rates of pathological response and similar 
clinical results.
MetHoDS anD MaterialS
Retrospective, single institution, case review study. Electronic 
medical records were searched for patient and treatment charac-
teristics, after Institutional Review Board approval.
Patients
Inclusion criteria: patients with Stage IIB to IIIB (American 
Joint Committee on Cancer seventh Edition) non-small cell 
lung cancer (NSCLC), who were treated at Sheba Academic 
Medical Center, Israel between August 2012 and August 2018 
with concurrent chemotherapy and external beam radiotherapy 
(CCRT), followed by surgery. Exclusion criteria were small 
cell lung cancer, metastatic disease, and patients who did not 
undergo completion surgery. We did include one patient with 
solitary brain metastasis that was treated with stereotactic brain 
radiosurgery. Information on follow-up was reviewed up to 
January 2019.
Treatment
Our institutional trimodality approach, as well as chemotherapy 
protocols and radiation planning objectives have been previously 
described.6 Briefly, positron emission tomography/CT (PET/CT) 
imaging for target delineation was used by image registration and 
fusion to the planning CT scan. Elective nodal irradiation was not 
used. Margins from gross tumor volume (GTV) to clinical target 
volume (CTV) was 0.5 cm, and from CTV to planning target 
volume (PTV) was 0.5–1 cm. Radiation dose was prescribed to 
60 Gy except if limited by organ-at-risk doses, or stopped early 
due to patients' side-effects. Tissue heterogeneity corrections 
were included in the treatment planning system. Dose calcula-
tions were performed using the analytical anisotropic algorithm 
(AAA) in the Eclipse (Varian Medical Systems, Palo Alto, CA, 
USA) treatment planning system. Radiation in both cohorts had 
a planned prescription goal of ≥95% of the treatment dose was 
prescribed volumetrically to >95% of the PTV.
Patients were categorized according to radiation treatment tech-
nique: 3DCRT vs IMRT. For the purpose of the analysis, IMRT 
and VMAT cases were combined together. Patients who were 
treated with a hybrid 3DCRT-IMRT plan were included in the 
IMRT cohort. Prior to 2016, our protocols included 3DCRT 
techniques except for tumors that were located close to the spine, 
in which case IMRT was preferred. Since the middle of 2016, 
IMRT has become the standard modality in our department for 
locally advanced lung cancer (LANSCLC) patients.
Daily image guided radiation therapy (IGRT) using daily kilo-
voltage imaging (kV/kV) or cone-beam CT (CBCT) was system-
atically applied to all lung cancer patients in our cohort. The 
choice of IGRT was according to physician guidance. For any 
patient, if more than 50% of images used were CBCT, it was listed 
in the CBCT group, and if less than 50% it was listed in the kV/
kV group.
Chemotherapy was prescribed concurrently with the radiation, 
with platinum doublet, at the choice of the medical oncologist. 
Standard treatment regimens were:
•	 Cisplatin (CN) (37.5 milligram/meter square (mg/m2) Day1, 
Day8, Day22, Day38) and vinorelbine (12.5 mg/m2 Day1, 
Day8, Day22, Day38)
•	 Carboplatin (CT) at area-under curve (AUC) two with 
paclitaxel at 45 mg/m2 both given every week or carboplatin at 
AUC 5 with paclitaxel 175 mg/m2 every 3 weeks q3w
•	 Etoposide (EP) at 100 mg/m2 Day1-3 with cisplatin at 75 mg/
m2 q3w or etoposide 50 mg/m2 Day1-5 with cisplatin 50 mg/
m2 Day1,Day8 q4w
Surgery: A complete anatomical resection with hilar and medi-
astinal lymph node dissection was performed 6-to-8 weeks 
following completion of CCRT. The preferred surgical approach 
was a muscle-sparing lateral thoracotomy.
Pathological analysis
Pathological endpoints were tumor-regression and the surgi-
cal-margin status.
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Pathological response was evaluated on the specimens according 
to protocols recommended by the College of American Pathol-
ogists, based on the modified tumor regression grading, as 
suggested by Junker et al.7 Response was recorded as a dichoto-
mous variable with ‘favorable' or ‘unfavorable' groups. Favorable 
pathological response included major tumor regression (MTR), 
defined as residual viable tumor estimated to be less than 10% of 
suspected area, or complete pathological response (pCR) if there 
were no viable tumor cells identified. Unfavorable pathological 
response was recorded if there was residual tumor of more than 
10%, or no response.
Additionally, a continuous variable was assessed, based on the 
average percentage area of residual tumor cells that remained 
as a proportion of the treatment-affected region of the excised 
lung. A pathological regression score was based on information 
from the primary tumor and the excised lymph nodes combined. 
Pathologic specimen scoring, performed by two senior patholo-
gists, was blinded to the techniques of radiation.
Clinical outcomes
Local control (LC) and disease free survival (DFS) were deter-
mined by radiological follow-up (CT or PET/CT). Patients who 
were lost to follow up were censored at the last date of follow up. 
Survival status was determined from the national health data-
base. We recorded episodes of acute toxicity (up to 3 months 
post-treatment) from the chemoradiation, according to the 
Common Terminology Criteria for Adverse Events version 4 
(CTCAE v4), as well as acute complications following surgical 
resection (3 months post- surgery).
Statistical analysis
Outcomes in the 3DCRT and IMRT groups were compared 
using non-parametric tests. We used the two-tailed chi-squared 
or Fisher exact test, as needed for dichotomous variables. For 
continuous variables that were normally distributed, the T-test or 
one-way ANOVA were used. Mann-Whitney or Kruskal-Wallis 
tests were used for non-parametric variables. The threshold of 
statistical significance was p<0.05. Kaplan-Meier estimation and 
log-rank regression, using STATA V.13 (StataCorp LLC) was 
used for survival analysis.
reSultS
Our cohort included 74 patients (Table  1). Mean age was 62.9 
years (range 45–79.7); 69% were male. Smoking status was: 
current smokers in 64.8% and past smokers in 14.8%. Histology 
was adenocarcinoma in 62.1% and squamous cell carcinoma 
in 28.3%. Clinical stages were IIB, III and IV in 18.9%, 79.7% 
and 1.2% respectively. Chemotherapy comprised CN, CT, EP in 
28.4%,58.1% and 9.5% respectively..
Radiation dose: mean 59.2 Gy; (SD ±3.8; range 46–72); 90.5% 
of all cases were treated to at least 54 Gy. The technique used 
for radiation treatment was 3DCRT in 68.9%, IMRT in 6.7% and 
VMAT in 24.3%. Surgery type included: lobectomy, lobectomy 
with chest wall resection and pneumonectomy in 70.3%, 12.1 
and 17.6% respectively.
Pathological response: favorable pathological response including 
pCR was observed in 48/74 patients (64.9%); unfavorable patho-
logical response was observed in 26/74 patients (35.1%).
The 3DCRT and the IMRT groups were comparable in all vari-
ables besides the IGRT (Table 1): in the 3DCRT group the IGRT 
was CBCT in 12/51 (23.5%) vs 14/23 (60.9%) in IMRT group (p 
< 0.001).
Tumor volumes and dosimetric parameters are presented in 
Table  2. The total tumor volume, the primary tumor (gross 
target volume, GTV) and the lymph node volumes were similar 
between the two groups. The dosimetric parameters including 
lung V20 (volume receiving above 20 Gy), mean lung dose and 
mean esophageal dose were similar between the treatment tech-
niques. The lung V5 (volume receiving above 5 Gy) was higher in 
the IMRT compared to 3DCRT group (53% vs 43.2%, p = 0.024). 
The PTV covered by 95% of the prescribed dose was higher in 
IMRT vs 3DCRT (97% vs 93.7%, p < 0.01). The mean heart dose 
in IMRT and 3DCRT groups was 7.2 Gy and 10.2 Gy respec-
tively (p = 0.53) and the volume of the heart receiving 45 Gy and 
above (heart V45) was smaller in IMRT compared to 3DCRT 
groups (2.1cc vs 7.5cc, p =0.06). The maximal dose to the spine 
was lower in IMRT vs 3DCRT (38.8Gy vs 42.89Gy p<0.005).
Pathological response and radiation technique 
(Figure 1)
Favorable pathological response was similar between radia-
tion techniques: for 3DCRT 32/51 (62.7%) and for IMRT 15/23 
(65.2%) (p = 0.83). The rate of pCR was also similar for 3DCRT 
(17/51,33.3%) and IMRT (8/23,34.8%) (p = 0.9). The average 
percentage area of residual tumor cells was also similar between 
the radiation techniques: for 3DCRT 16% (SD ±25.5) and for 
IMRT 22% (SD ±27.2) (p = 0.36).
Margins were negative in 90.1% (46/51) of patients treated with 
3DCRT compared to 89.4% (17/19) with IMRT (p = 1.0).
Clinical outcome and radiation technique
At median follow-up of 3.6 years, the 2-year overall survival for 
3DCRT was 82% (95% CI, 68–90%) and for IMRT was 85% (95% 
CI, 60–95%) (p = 0.72). 2-year overall LC rates were 81.6% (95% 
CI, 69–89.4%), DFS 58.3% (95% CI, 45.5–69%) and 3-year OS 
70% (95% CI, 57–80%). Comparing radiation techniques, there 
were no significant differences in LC (p = 0.94), DFS (p = 0.33) or 
OS (p = 0.72). (Figure 2a,b,c).
DFS differed according to the pathological response. With ‘favor-
able' pathological response, 2-year DFS was 71.9% (95% CI, 
55–83%) compared to 35.3% (95% CI, 17.4–53.8%) in the ‘unfa-
vorable' pathological response group (p = 0.01); HR 2.45 (95% 
CI, 1.24–4.8) (Figure 2d).
OS at 2 years was also better if there was a favorable patho-
logical response: 86.3% (95% CI, 72–93.6%) vs 74.8% (95% 
CI, 52–87.7%) with an unfavorable pathological response, but 
this difference did not reach statistical significance (p = 0.29). 
(Figure 2e).
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Table 1. Patients’ characteristics, disease and treatment details
Parameter N (%) 
total 74
3DCRT total 51 IMRT total 23 p value
N (%) N (%)
Age
  Mean years, (range) 62.9 (45–79.7) 63.2 (45–79.7) 62.2 (47.3–75.6) NS (p = 0.9)
Gender
  Male 51 (69%) 38 (74.5%) 13 (56.5%) NS (p = 0.09) 
  Female 23 (31%) 13 (25.5%) 10 (43.6%)
Smoking status
  Current 48 (64.8%) 35 (68.6%) 13 (56.5%) NS (p = 0.40) 
  Past 11 (14.8%) 8 (15.7%) 3 (13%)
  Never 13 (17.5%) 7 (13.7%) 6 (26.1%)
  Missing 2 (2.7%) 1 (1.9%) 1 (4.3%)
Histology
  Squamous cell carcinoma 21 (28.3%) 17 (33.3%) 4 (17.4%) NS (p = 0.33) 
  Adenocarcinoma 46 (62.1%) 30 (58.8%) 16 (69.5%)
  Other 7 (9.4%) 4 (7.8%) 3 (13%)
Stage
  II 14 (18.9%) 10 (19.6%) 4 (17.4%) NS(p = 0.79) 
  III 59 (79.7%) 40 (78.4%) 19 (82.6%)
  IV 1 (1.2%) 1 (2%) 0 (0%)
Chemotherapy
  CN 21 (28.4%) 19 (37.2%) 2 (8.7%) p = 0.15 
  CT 43 (58.1%) 27 (53%) 16 (69.6%)
  EP 7 (9.5%) 3 (5.9%) 4 (17.4%)
  Other 2 (2.7) 1 (2%) 1 (4.3%)
  Not received 1 (1.4%) 1 (1.9%) 0 (0%)
Surgery
  Lobectomy 52 (70.3%) 35 (68.6%) 17 (74%) NS (p = 0.82) 
  Chest wall resection 9 (12.1%) 6 (11.7%) 3 (13%)
  Pneumonectomy 13 (17.6%) 10 (19.6%) 3 (13%)
Pathological response
  Complete response 25 (33.8%) 17 (33.3%) 8 (32%) NS (p = 0.83) 
  <10% residual 23 (31%) 16 (31.4%) 7 (30.5%)
  >10% residual 21 (28.3%) 14 (27.5%) 7 (33.4%)
  No response 5 (6.7%) 4 (7.8%) 1 (20%)
Average percent of pathological 
residual tumor cells
  (mean ± SD) 17.8% (SD ± 26) 16% (SD ± 25.5) 22% (SD ± 27.2) NS (p = 0.36)
Margin
  Negative 67 (90.5%) 46 (90.2%) 20 (87%) NS (p = 1) 
  Positive 6 (8.1%) 5 (9.8%) 2 (8.7%)
  Missing 1 (1.4%) 0 (0%) 1 (4.3%)
(Continued)
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Toxicities and complications
Grade 2 acute esophageal toxicity from radiation was lower with 
IMRT (32% compared to 37% with 3DCRT, p = 0.66). Grade 4 
esophagitis was recorded in 4% in 3DCRT vs 0% in IMRT (p = 
0.53). Respiratory side-effects were recorded in 8% 3DCRT and 
5% IMRT (p = 0.6) (Supplementary Table 1).
Acute complications from surgery were: respiratory 36% in both 
modalities. Chest wall necrosis occurred in three cases and bron-
cho-pleural fistula in five cases (all in the 3DCRT group). Grade 
5 surgical complications occurred in two patients in the 3DCRT 
group (2.7% of total 74 patients). Both of them underwent right 
pneumonectomy (Supplementary Table 1).
IGRT
  kV/kV 47 (63.5%) 39 (76.5%) 8 (34.8%) p < 0.001 
  CBCT 26 (35.1%) 12 (23.5%) 14 (60.9%)
  Missing 1 (1.4%) 0 (0%) 1 (4.3%)
3DCRT. 3 dimensional conformal radiation; IMRT, intensity modulated radiation therapy; SD, standard deviation; NS, not significant; CN, 
cisplatin-vinorelbine; CT, carboplatin-paclitaxel; EP, etoposide-cisplatin; IGRT, image guided radiation therapy; Kv/Kv, kilovoltage imaging; 
CBCT, cone beam CT.
Table 1 (Continued)
Table 2. Comparison of Tumor Volumes and Dosimetric parameters between 3DCRT and IMRT
Mean ± SD
(Median, range) P value
Total tumor volume (cc) 3DCRT 169.6 ± 124.7 (152, 16–168) 0.14
IMRT 133 ± 122.2 (77–432)
Gross tumor volume GTV (cc) 3DCRT 135.2 ± 134.8 (99, 0–685) 0.26
IMRT 99.8 ± 115.5 (40, 2–418)
Lymph node volume (cc) 3DCRT 34.3 ± 42 (25, 0-182) 0.6
IMRT 33.2 ± 34.7 (24.5, 0–145)
Prescribed dose (Gy) 3DCRT 58.9 ± 3.4 (60,48–66) p = 0.31
IMRT 60 ± 4.7 (60, 46.2–72)
PTV D95 (%) 3DCRT 93.7 ± 4 (95, 78–99) <0.01
IMRT 97 ± 3.4 (98.6, 88.5–100)
Lung V20 (%) 3DCRT 23.4 ± 6.7 (24, 4–37) 0.75
IMRT 24 ± 5.2 (24.4, 6.6–32.5)
Mean lung dose (Gy) 3DCRT 13.7 ± 3.70 (14, 3-28) 0.613
IMRT 14.17 ± 2.88 (14, 4–17.4)
Lung V5 (%) 3DCRT 43.4 ± 17 (38, 10-81) 0.02
IMRT 53.5 ± 11.5 (56.2, 13–66)
Heart 45 (cc) 3DCRT 7.5 ± 11.1 (2.3, 0–47) 0.06
IMRT 2.1 ± 3.6 (0.5, 0–12.6)
Mean heart dose (Gy) 3DCRT 10.24 ± 10.18 (6.15, 0–34) 0.53
IMRT 7.2.18 (5.5, 0–19.5)
Mean esophageal dose (Gy) 3DCRT 19.96 ± 9.63 (20, 0-47) 0.86
IMRT 20.15 ± 5.95 (20.9, 8.4–29.7)
Spine max dose (Gy) 3DCRT 42.89 ± 10.36 (47.6, 4.4–54) 0.005
IMRT 38.8 ± 8.10 (40.5,21–49.3)
3DCRT, 3 dimensional conformal radiation; IMRT, intensity modulated radiation therapy; Gy, radiation units in Gray; PTV. planning target volume; 
D95, volume covered by 95% of the dose; LungV20, volume receiving above 20 Gy; LungV5, volume receiving above 5 Gy; Heart 45, heart volume 
receiving dose above 45 Gy.
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DiSCuSSion
Compared to 3DCRT, IMRT offers improved target coverage 
and reduced doses to organ at-risk by using complex modu-
lated radiation beams. However, in lung cancer therapy there has 
been concern regarding the ‘interplay effect’ that may potentially 
reduce the actual dose delivered to the tumor.
In this study we found that for NSCLC, 3DCRT and IMRT 
techniques resulted in similar pathologic response, negative 
margins, local control, disease free and overall survival. This data 
adds support to the effectiveness of IMRT compared to 3DCRT 
modalities in treating LANSCLC.
In a dosimetric study, Bortfeld et al found that for a typical 
treatment with 30 fractions, the standard deviation of the deliv-
ered dose is generally within 1% of the expected value for dose 
delivery if one assumes a typical motion amplitude of 5 mm (1 cm 
peak-to-peak) due to averaging of the dose in fractionated IMRT 
planning. This is the same as for treatments with conventional 
static beams.8 Therefore, the final dose delivered to the target and 
normal tissue is expected to be similar to that for conventional 
radiotherapy delivered without intensity modulation, and the 
additional effects specific to the IMRT delivery technique seem 
to be relatively small.
To our knowledge this study is the first report of compar-
ison between these techniques, using pathologic regression 
scoring after 60 Gy chemoradiation to LANSCLC, thus, further 
supporting the previously reported dosimetric studies.
In a study by Pataer et al, the percentage of residual viable tumor 
cells and surgical pathologic stage were associated with OS. Long-
term OS and DFS were significantly prolonged in patients who 
had ≤10% viable tumor cells (favorable response) compared with 
patients with >10% viable tumor cells (unfavorable response); 
with 5-year OS 85% vs 40% (p < 0.0001) and 5-year DFS 78 
vs 35% (p < 0.001), making this cut-point a clinically relevant 
endpoint to measure.9 Our study also confirmed a statistically 
significant increase in DFS in the favorable pathologic response 
group, with doubling of the 2-year DFS from 35.3 to 71.9% (HR 
2.45 p = 0.01).
The feasibility of NSCLC treatment with chemoradiation to high 
dose (60 Gy) in the neoadjuvant setting has been reported. The 
RTOG 0229 Phase II trial prescribed “full-dose” concurrent 
chemoradiation (i.e. 60 Gy) followed by resection. Mediastinal 
pathological clearance was observed in 63% of patients, similar 
to our finding of 64.8% major tumor regression. There was a 14% 
(5/37) incidence of grade 3 postoperative pulmonary compli-
cations and only one postoperative grade 5 adverse event (3%), 
comparable to our surgical complication rates. Similarly, they 
reported a 2-year OS of 75% for those who achieved nodal clear-
ance vs 52% for those with residual nodal disease.10
In our study we observed lower rates of serious surgical compli-
cations in IMRT vs 3DCRT: grade 4 complications in 6% with 
3DCRT compared to0% in IMRT and grade 5 complications in 
2 out of 51 patients (4%) in 3DCRT compared to 0% in IMRT. 
This may be explained by the improved conformity and homoge-
neity of the IMRT planning technique compared to 3DCRT but 
requires validation in a larger cohort.
Moreover, we found reduced rates of esophagitis as well as respi-
ratory toxicity in the IMRT group. In a retrospective study by 
Yom et al, reduced grade ≥3 pneumonitis was seen in IMRT 
compared to 3DCRT (8% vs 32%).11 The RTOG 0617, a prospec-
tive, randomized phase III trial, compared definitive chemo-
radiation to 60 Gy vs 74 Gy. They observed that the decline in 
quality-of-life was significantly reduced with the use of IMRT, 
suggesting that improved radiation technique may help enhance 
the therapeutic window for patients with lung cancer.12 In a 
secondary analysis of this pivotal trial, 2-year OS, LC and PFS 
were compared between IMRT and 3DCRT, and, as concluded 
in this study, found to be similar between techniques. Further-
more, Chun et al also reported reduced pneumonitis with IMRT 
compared with 3DCRT (7.9% vs 3.5%, p = 0.04) and lower heart 
doses (p < 0.05). In fact, their study suggested that the volume 
of heart receiving high-dose was associated with OS (p < 0.05), 
further supporting routine use of IMRT for locally advanced 
NSCLC.13 In our analysis the volume of the heart receiving high-
dose was also lower in IMRT than in 3DCRT (p = 0.06).
Two population-based studies have shown IMRT to be asso-
ciated with significantly decreased incidence of pulmonary 
toxicity, reduced esophagitis rate and fewer placements of percu-
taneous gastric feeding tubes.14,15 Reduced incidence of esoph-
agitis may also be the result of dose de-escalation to the lymph 
nodes. According to Van de Bosch et al, lymph node control may 
be achieved at lower radiation doses than needed for the primary 
tumor.16
Comparative effectiveness between 3DCRT and IMRT for stage 
III NSCLC has been assessed in population-based studies, with 
the two techniques found to be similar in local control and 
survival in the definitive setting (without completion surgery). 
Shirvani et al found that based on the SEER-Medicare database, 
IMRT was associated with similar oncologic outcomes to those 
Figure 1. The pathological response by radiation treatment 
technique.
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of 3DCRT15 and even improved overall survival compared to 
3DCRT in cases of large tumors.14
In our study the IGRT was correlated to the technique: daily 
CBCT was performed in 14/22 (63.6%) of the IMRT group 
compared to only 23.5% with 3DCRT. Volumetric imaging, in 
particular, CBCT offers more precise localization of soft tissue 
targets and critical organs which reduces setup uncertainty and 
permits the use of smaller volumes and complex planning. This 
has real implications for radiotherapy's therapeutic ratio. Bisson-
nette et al showed that using IGRT, high geometric accuracy is 
achievable for NSCLC patients, potentially leading to reduced 
PTV margins.17 Furthermore, in a retrospective trial, Kilburn 
et al demonstrated a substantial local control increase of 16% 
for patients treated with IGRT using daily kV/kV or CBCT 
compared to weekly MV portal imaging.18
Limitations of this study include the retrospective design and 
single-center cohort, making generalization of the results to other 
cancer centers limited. However, the use of uniform methods 
of radiotherapy planning and blinded pathologic reporting 
strengthen our findings.
Since prospective randomized trials comparing these techniques 
are unlikely to be conducted, this study adds evidence for the 
comparative effectiveness of IMRT in lung radiation therapy 
Figure 2. Kaplan Meier survival estimates of (a) Local Control (b) Disease Free Survival and (c) Overall Survival according to treat-
ment technique, and disease free survival (d) and overall survival (e) according to pathological regression. 3DCRT, three dimen-
sional conformal radiation therapy; IMRT intensity modulated radiation therapy.
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based on NSCLC pathological specimens that were excised after 
60 Gy chemoradiation.
In conclusion, for the first time we have demonstrated the 
comparative effectiveness of IMRT and 3DCRT for LANSCLC, 
according to pathological specimens, in the trimodality treat-
ment strategy.
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